NanoVibronix Launches "Oscar" Training Aid to Accelerate ENvue Adoption and Unlock New Revenue Opportunities
Training platform accelerates onboarding, expands distribution potential and better positions Company for growth
NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today announced the launch of Oscar, an advanced training aid, introduced through its ENvue Medical ("ENvue" or "ENvue Medical") division. Oscar is designed to provide clinicians and educators with a standardized, repeatable approach to practicing naso-enteral feeding procedures, addressing a key barrier to adoption of new and current technologies.
"We believe that Oscar enhances our ENvue® system offering by providing hospital training centers with the educational support they need to accelerate adoption," said Doron Besser, M.D., Chief Executive Officer of NanoVibronix. "Training remains one of the primary obstacles hospitals face when adopting new technologies or practicing standard procedures. We believe that Oscar directly addresses this challenge by giving clinicians a safe, consistent and repeatable platform for practice prior to working with patients. This reduces onboarding time and resources while enabling faster, broader adoption of ENvue."
Besser continued, "We believe Oscar provides a strong point of differentiation in the marketplace. By combining our advanced navigation system with Oscar's training and support framework, we are better positioned to drive success of implementations, strengthen hospital relationships and open new growth opportunities."
Unlike the Company's FDA-cleared ENvue System, Oscar is not classified as a medical device. The Company plans to incorporate Oscar as a teaching aid for ENvue while also making it available independently to teaching hospitals, nursing schools and training facilities, creating multiple channels for market penetration and revenue generation.
Besser added, "We expect broader availability beginning in 2026, when Oscar will begin contributing directly to revenue through training programs while also accelerating ENvue adoption. We believe this dual impact expands our growth opportunities, supports broader distribution and creates meaningful opportunities for incremental revenue for the Company."
About NanoVibronix, Inc.
NanoVibronix, Inc. (NASDAQ:NAOV) is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Headquartered in Tyler, Texas, with research and development in Nesher, Israel, the Company focuses on two distinct technology platforms:
- Acoustic-based therapeutic technologies, including PainShield® and UroShield®, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms.
- ENvue™ Navigation Platform, developed and operated by ENvue Medical, with offices in Arlington Heights, Illinois, and Tel Aviv, Israel, is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. FDA 510(k) cleared for adult use, ENvue provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure. Future platform expansion may include pediatric and vascular access applications.
NanoVibronix aims to advance standards in non-invasive therapy and minimally invasive navigation, with a commitment to patient safety, clinical usability, and technology innovation across a range of healthcare environments.
Forward-Looking Statements
This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words. These forward-looking statements include, but are not limited to: statements regarding the adoption and implementation of ENvue Medical's platforms, anticipated commercial expansion and implementation of ENvue Medical's products, the incorporation of Oscar as a training model and availability, market interest in the Company's technology, and future expectations for strategic growth. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: (i) market acceptance of the Company's existing and new products; (ii) clinical performance and operational outcomes; (iii) delays or complications in product implementation; (iv) intense competition in the medical device industry; (v) product liability or performance issues; (vi) limitations in manufacturing or supply chain capabilities; (vii) reimbursement limitations; (viii) intellectual property protection; (ix) healthcare regulatory changes in the U.S. and abroad; and (x) the need for additional capital. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission ("SEC"), including the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Investors and security holders are urged to read these documents free of charge at: www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250918999113/en/
Brett Maas, Managing Principal
Hayden IR, LLC
[email protected]
(646) 536-7331